Core Viewpoint - Weigao Orthopedics (688161.SH) reported a revenue of 1.539 billion yuan for the fiscal year 2025, marking a year-on-year growth of 5.95%, with a net profit attributable to shareholders of 267 million yuan, up 19.17% from the previous year [1] Financial Performance - The company achieved a net profit of 252 million yuan after deducting non-recurring gains and losses, reflecting a year-on-year increase of 19.59% [1] - Excluding share-based payment expenses, the net profit attributable to shareholders was approximately 296 million yuan, representing a growth of about 32.13% [1] - The net profit after excluding non-recurring gains and losses was around 281 million yuan, with a year-on-year increase of approximately 33.34% [1] Sales Strategy - The company is actively adjusting its sales model and organizational structure, focusing on a profit center system centered around professional departments to enhance sales organization vitality [2] - Product lines are further segmented through sales divisions, improving the professional capabilities and focus of the sales team for more precise clinical services and academic leadership [2] - The company is focusing on key surgical procedures with multi-product line collaborative sales, leading to significant growth in core hospital business and increased efforts in developing lower-tier markets and promoting innovative products [2] Research and Development - The company maintains stable and continuous investment in R&D, increasing input in orthopedic biomaterials, intelligent devices, and minimally invasive consumables to drive innovation in the next generation of orthopedic products [2] - Ongoing efforts are made to promote the localization of raw materials for orthopedic consumables and improve R&D processes, gradually achieving quality enhancement and cost reduction [2] Production and Operations - The company is enhancing digital construction and building operational system platforms, significantly improving supply chain efficiency [2] - Through refined management, the company continues to reduce costs and increase efficiency, contributing to rapid growth in net profit [2]

Core Viewpoint - Weigao Orthopedics (688161.SH) reported a revenue of 1.539 billion yuan for the fiscal year 2025, marking a year-on-year growth of 5.95%, with a net profit attributable to shareholders of 267 million yuan, up 19.17% from the previous year [1] Group 1: Financial Performance - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 252 million yuan, reflecting a year-on-year increase of 19.59% [1] - After adjusting for share-based payment expenses of approximately 29 million yuan from the 2025 restricted stock incentive plan, the net profit attributable to shareholders was about 296 million yuan, representing a growth of approximately 32.13% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was approximately 281 million yuan, with a year-on-year growth of about 33.34% [1] Group 2: Sales and Marketing Strategy - The company is actively adjusting its sales model and organizational structure, focusing on a profit center system centered around professional departments to enhance marketing efficiency [2] - There is a further segmentation of product lines through detailed management by sales divisions, improving the professional capabilities and focus of the sales team for more precise clinical services and academic leadership [2] - The company is focusing on key surgical procedures with multi-product line collaborative sales, resulting in significant growth in core hospital business and increased efforts in developing lower-tier markets and promoting innovative products [2] Group 3: Research and Development - The company maintains stable and continuous investment in R&D, increasing input in orthopedic biomaterials, intelligent devices, and minimally invasive consumables to drive innovation in the next generation of orthopedic products [2] - There is a continuous push for the localization of raw materials for orthopedic consumables and improvements in R&D processes to gradually achieve quality enhancement and cost reduction [2] Group 4: Production and Operations - The company is enhancing digital construction and building operational system platforms, significantly improving supply chain efficiency [2] - Through refined management, the company is continuously reducing costs and increasing efficiency, contributing to rapid growth in net profit [2]